Beyond titer: using next-generation sequencing to see what is really inside our viral vectors
Published in Bioengineering & Biotechnology, Microbiology, and General & Internal Medicine
Closer inspection often reveals a more complicated picture. Vector preparations can contain truncated or chimeric genomes, packaged plasmid backbone, host cell DNA, helper sequences, and low-frequency variants in the transgene or regulatory elements. These can affect potency, immunogenicity, and safety, and most are invisible to conventional assays.
Next-generation sequencing (NGS) can resolve this heterogeneity. Long-read platforms read intact vector genomes from single molecules, and deep short-read sequencing profiles impurities and rare variants. Applied carefully, with attention to library prep artifacts, error models, and orthogonal confirmation, NGS can turn vector characterization from a bulk measurement into a detailed, quantitative picture.
I am planning a peer-reviewed publication on this topic and am looking for co-authors and experimental partners. I will lead the project strategy, study design, data analysis, and writing. I am looking for collaborators who can contribute samples, sequencing capacity, or domain expertise (vector biology, bioinformatics, or CMC assay validation) to make the work rigorous and useful for the field.
If this overlaps with your work, please comment below or contact me at [email / ORCID / institution]. Tell me about your vector or dataset, what you could contribute, and the role you would like on the paper.
I am a molecular biologist with a strong record of contributions in gene therapy analytics and microbial genomics. During my Ph.D. at Sardar Patel University, India, I studied the microbial ecology of extreme environments, uncovering unique microbial community structures, functional dynamics, and stress-tolerance pathways. This work resulted in five peer-reviewed publications in high-impact journals such as Science of the Total Environment, Applied Biochemistry and Microbiology, and Environment Technology & Innovation.
In industry, I developed and validated analytical methods for AAV and lentiviral vectors, supporting regulatory submissions for gene therapy products. My contributions improved assay accuracy for genome quantification, potency, and purity testing, accelerated product development timelines, and ensured compliance with GMP and ICH standards.
I am an active peer reviewer for journals including BMC Genomics, Scientific Reports, World Journal of Microbiology and Biotechnology, Environmental Monitoring and Assessment, and Frontiers in Marine Science, demonstrating sustained engagement with the scientific community. My work bridges fundamental microbial insights with translational applications in viral vector therapeutics and biotechnology.
